Clinical Trial Update: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas [Phase 2]

View source ↗

Summary

Clinical trial update indicates a Phase 2 study of the JAK1 inhibitor golidocitnib for relapsed/refractory indolent T- and NK-cell lymphomas, with recruitment o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Acral Cd8-positive T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
• Large Granular Lymphocytic Leukemia
• Mycosis Fungoides
• Natural Killer Cell Large Granular Lymphocytic Leukemia
• T-cell Large Granular Lymphocytic Leukemia

Drugs mentioned

• Golidocitnib (golidocitnib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Status: RECRUITING